Arcutis Biotherapeutics, Inc. — Q2 2020 Form 10-Q
Reporting period: Three and six months ended June 30, 2020. Financial statements are unaudited. Arcutis is a clinical-stage biopharmaceutical company developing topical treatments for dermatological diseases; it has no approved products and has generated no product revenue.
Financial performance and liquidity
| Metric | Q2 2020 | Q2 2019 | Six months 2020 | Six months 2019 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $30.0 million | $7.2 million | $55.2 million | $13.4 million |
| General and administrative expense | $5.6 million | $1.3 million | $9.1 million | $2.1 million |
| Net loss | $35.4 million | $8.3 million | $63.4 million | $14.9 million |
| Net loss per share, basic and diluted | $0.94 | $4.69 | $2.05 | $8.79 |
| Net cash used in operating activities | Not separately provided | Not separately provided | $46.8 million | $15.3 million |
As a pre-revenue company, the filing does not present meaningful gross margins or operating margins. Other income was $0.2 million in Q2 and $0.9 million for the first half of 2020.
At June 30, 2020, cash and cash equivalents were $171.5 million and marketable securities were $52.4 million, totaling $224.0 million. Current assets were $228.0 million versus current liabilities of $19.3 million. Total liabilities were $23.0 million; the company reported no debt. Accumulated deficit was $129.7 million.
Changes versus prior comparable periods
- Q2 operating expenses rose 317% year over year and net loss increased $27.1 million. Management attributed higher R&D spending mainly to clinical-trial costs, particularly the Phase 3 psoriasis program, and also to manufacturing, staffing, and other development costs.
- First-half operating cash use increased to $46.8 million from $15.3 million, reflecting expanded operations and development activity.
- The February 2020 IPO generated approximately $167.2 million in net proceeds as described by management. Preferred shares converted into common stock at the IPO; common stock issued increased substantially.
Outlook, commentary, and risks
- Management expected existing cash, cash equivalents, and marketable securities to fund planned operations through 2021. It also expects continuing losses and says additional capital will be needed for future operations.
- Roflumilast cream was in three Phase 3 plaque-psoriasis studies, with topline results expected in the first half of 2021. The company expected full-population long-term safety data in Q1 2021 and planned an atopic-dermatitis Phase 2b study in the second half of 2020.
- Roflumilast foam studies in seborrheic dermatitis and scalp psoriasis had topline data expected in Q4 2020. ARQ-252 was in a Phase 1/2b hand-eczema study, with data expected in the second half of 2021; a vitiligo study was planned for the second half of 2020. ARQ-255 remained in formulation and preclinical work.
- COVID-19 had caused limited disruption to screening, enrollment, and monitoring. Management did not then expect delays to previously disclosed clinical timelines, but cautioned that the full impact was uncertain. It reported no drug-supply disruptions and believed available inventory could support ongoing trials.
- A disclosed Phase 2 proof-of-concept study of roflumilast cream in atopic dermatitis did not meet statistical significance for its primary endpoint or the IGA Success secondary endpoint; the company reported significance on certain other secondary efficacy endpoints. Later studies may not reproduce those results.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, reliance on third-party manufacturers and CROs, competition, future financing needs and potential dilution, and milestone and royalty obligations under AstraZeneca and Hengrui licenses. The company reported no material litigation and no off-balance-sheet arrangements.
Investor verification priorities
- Check actual trial progress and results against the stated timelines, including the Phase 3 psoriasis studies and the mixed atopic-dermatitis Phase 2 findings.
- Monitor cash burn, development spending, and whether the stated runway through 2021 remains achievable; confirm the timing and terms of any additional financing.
- Reconcile share counts and potential dilution: the balance sheet reports 37.7 million common shares outstanding at June 30, while the cover page reports 38.2 million shares outstanding as of August 1.
- Track license-related milestone, royalty, and sublicensing obligations, as well as manufacturing capacity and dependence on third parties.